Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

Acta Neuropathologica

Volumn 129, Issue 5, 2015, Pages 679-693

  Weller, Michael ^a,b   Weber, Ruthild G ^c   Willscher, Edith ^d   Riehmer, Vera ^c   Hentschel, Bettina ^d   Kreuz, Markus ^d   Felsberg, Jörg ^e   Beyer, Ulrike ^c   Löffler Wirth, Henry ^d   Kaulich, Kerstin ^e,f   Steinbach, Joachim P ^b,f,g   Hartmann, Christian ^c,h   Gramatzki, Dorothee ^a   Schramm, Johannes ⁱ   Westphal, Manfred ^j   Schackert, Gabriele ^k   Simon, Matthias ⁱ   Martens, Tobias ^j   Boström, Jan ⁱ   Hagel, Christian ^j   Sabel, Michael ^l   Krex, Dietmar ^k   Tonn, Jörg C ^m   Wick, Wolfgang ⁿ   Noell, Susan ^o   Schlegel, Uwe ^p   Radlwimmer, Bernhard ^f   Pietsch, Torsten ⁱ   Loeffler, Markus ^d   von Deimling, Andreas ^h   Binder, Hans ^d   Reifenberger, Guido ^e,f   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITY OF BONN   (Germany)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^l Department of Orthopedic Surgery   (Germany)

^m UNIVERSITY OF MUNICH   (Germany)

ⁿ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^o UNIVERSITY OF TÜBINGEN   (Germany)

^p RUHR UNIVERSITY BOCHUM   (Germany)

more..

Author keywords

1p 19q co deletion; Array based comparative genomic hybridization; Astrocytoma; Gene expression profiles; Integrative bioinformatics; Isocitrate dehydrogenase; Oligodendroglioma

Indexed keywords

IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ADULT; AGED; BRAIN TUMOR; CANCER GRADING; CLASSIFICATION; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; GLIOMA; HUMAN; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS; PROMOTER REGION; VERY ELDERLY; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PROGNOSIS; PROMOTER REGIONS, GENETIC; SEQUENCE DELETION; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 84939952838     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-015-1409-0     Document Type: Article

References (43)

1. Bourne TD, Schiff D (2010) Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 6:695–701
2. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714
3. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343
4. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG et al (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32:783–790
5. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T et al (2010) The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS ONE 5:e12548
6. Ducray F, Criniere E, Idbaih A, Mokhtari K, Marie Y, Paris S et al (2009) Alpha-Internexin expression identifies 1p19q codeleted gliomas. Neurology 72:156–161
7. Ducray F, Idbaih A, de Reynies A, Bieche I, Thillet J, Mokhtari K et al (2008) Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 7:41
8. Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M et al (2009) Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 15:6683–6693
9. Felsberg J, Wolter M, Seul H, Friedensdorf B, Goppert M, Sabel MC et al (2010) Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 119:501–507
10. Fuller CE, Schmidt RE, Roth KA, Burger PC, Scheithauer BW, Banerjee R et al (2003) Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol 62:1118–1128
11. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718
12. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 118:469–474
13. Hopp L, Wirth H, Fasold M, Binder H (2014) Portraying the expression landscapes of cancer subtypes: A glioblastoma multiforme and prostate cancer case study. SystemsBiomedicine 1:22
14. Ichimura K, Schmidt EE, Goike HM, Collins VP (1996) Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13:1065–1072
15. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722
16. Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ et al (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45:927–932
17. Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA et al (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515–1525
18. Killela PJ, Pirozzi CJ, Reitman ZJ, Jones S, Rasheed BA, Lipp E et al (2014) The genetic landscape of anaplastic astrocytoma. Oncotarget 5:1452–1457
19. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT et al (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126:907–915
20. Kreuz M, Rosolowski M, Berger H, Schwaenen C, Wessendorf S, Loeffler M et al (2007) Development and implementation of an analysis tool for array-based comparative genomic hybridization. Methods Inf Med 46:608–613
21. Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615–625
22. Louis DN, Ohgaki H, Wiestler B, Cavenee WK (2007) WHO classification of tumours of the central nervous system. IARC Press, Lyon
23. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A et al (2014) International society of neuropathology-haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24:429–435
24. Mukasa A, Ueki K, Ge X, Ishikawa S, Ide T, Fujimaki T et al (2004) Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss. Brain Pathol 14:34–42
25. Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19:764–772
26. Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H et al (2014) Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J Cancer 135:1822–1831
27. Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S et al (2014) Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 128:551–559
28. Shaw EJ, Haylock B, Husband D, du Plessis D, Sibson DR, Warnke PC et al (2011) Gene expression in oligodendroglial tumors. Cell Oncol (Dordr) 34:355–367
29. Tews B, Felsberg J, Hartmann C, Kunitz A, Hahn M, Toedt G et al (2006) Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer 119:792–800
30. van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol 120:297–304
31. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350
32. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722
33. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110
34. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27:5743–5750
35. Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R (2013) Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 14:e370–e379
36. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880
37. Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B et al (2013) Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81:1515–1522
38. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451
39. Wiestler B, Capper D, Hovestadt V, Sill M, Jones DT, Hartmann C et al (2014) Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro Oncol 16:1630–1638
40. Wiestler B, Capper D, Sill M, Jones DT, Hovestadt V, Sturm D et al (2014) Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 128:561–571
41. Wirth H, Loffler M, von Bergen M, Binder H (2011) Expression cartography of human tissues using self organizing maps. BMC Bioinf 12:306
42. Wirth H, von Bergen M, Binder H (2012) Mining SOM expression portraits: feature selection and integrating concepts of molecular function. BioData Min 5:18
43. Zielinski B, Gratias S, Toedt G, Mendrzyk F, Stange DE, Radlwimmer B et al (2005) Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization. Genes Chromosomes Cancer 43:294–301